Key result
SGLT2 inhibitors, MRAs, and GLP-1RAs are becoming integral to CVD and heart failure management, offering prognostic benefits for patients with T2DM and CKD.
Why the study?
CVD remains the leading cause of morbidity and mortality worldwide with rising multimorbidity from T2DM, CKD, and HF, prompting the need to review emerging evidence for SGLT2 inhibitors, non-steroidal MRAs, and GLP-1RAs.
SGLT2 inhibitors, non-steroidal MRAs, and GLP-1RAs represent a paradigm shift in managing patients with overlapping cardiovascular disease, heart failure, diabetes, and chronic kidney disease.
Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide. Epidemiological data demonstrate that the overlap between CVD, Type 2 Diabetes (T2DM), chronic kidney disease (CKD) and heart failure (HF) is becoming increasingly apparent, with aging populations making these patient cohorts more difficult to treat. In the last decade, three standout drug classes have emerged with the potential to broaden the treatment options for patients with multi-morbid CVD and heart failure. These are sodium–glucose cotransporter 2 (SGLT2) inhibitors, non-steroidal mineralocorticoid receptor antagonists (MRAs), e.g., Finerenone, and glucagon-like peptide 1 receptor agonists (GLP-1RAs). These medications are now entering UK and European guidelines for the treatment of CVDs including HF whilst crucially providing associated prognostic benefits for patients with T2DM and CKD. The future of these agents for CVD risk stratification may involve primary care at the forefront, alongside tailored, patient-specific medication regimens. This review article aims to discuss these three main drug classes (SGLT2 inhibitors, GLP-1RAs and non-steroidal MRAs) in detail by exploring their current evidence base across heart failure (HF) and CVD management and future clinical implications of their usage as mainstream medical therapies.
No takes yet. Share an insight, caveat, or question.
Oswald et al. (2025) studied this question. SGLT2 inhibitors, MRAs, and GLP-1RAs are becoming integral to CVD and heart failure management, offering prognostic benefits for patients with T2DM and CKD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: